Primary efficacy endpoint: estimate and CIs for differences in ACR20 response rate at week 12 and week 24 (FAS)
| n | Proportion (%) | Difference in proportions (BI 695501 – Humira, %) | |||
| Estimate | CI | ||||
| Week 12 | BI 695501 | 321 | 67.0 | 5.9 | 90% CI (−0.9 to 12.7) |
| Humira | 318 | 61.1 | |||
| Week 24 | BI 695501 | 321 | 69.0 | 4.5 | 95% CI (−3.4 to 12.5) |
| Humira | 318 | 64.5 | |||
ACR20, American College of Rheumatology 20%; FAS, full analysis set.